Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA^® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

03/20/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 57,500 shares of
03/05/20	Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020 REDWOOD CITY, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m. ET , being held in Miami .
03/05/20	United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand – US-based supply chain mitigates coronavirus-related disruption risks – – UDENYCA ® current inventory of over 300,000 syringes – REDWOOD CITY, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its United States
02/27/20	Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results – Full Year UDENYCA ® Sales of $356.1 Million – – Full Year Cash Flow from Operating Activities of $28.4 million – REDWOOD CITY, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial

View All